Inflammatory Bowel Disease Clinical Trial
Official title:
Studying the Role of B Cells in Inflammatory Bowel Disease (IBD), Using a Combination of Experimental and Bioinformatical Techniques.
Our overall objective in this study is to study the role of B cells in inflammatory bowel
disease (IBD), using a combination of high-throughput experimental and novel bioinformatical
techniques.
Idiopathic IBD includes Crohn's disease (CD) and Ulcerative Colitis (UC), which are chronic
inflammatory disorders of the intestine. IBD is common in developed countries, with up to 1
in 200 of individuals affected by theses diseases. It is currently thought that the disease
arises owing to a complex array of genetic, environmental and immunologic susceptibility
factors. T cells are thought to cause the lesions, but the B cell population apparently has
a significant role as well, through secreting antibodies against certain self-antigens. We
believe that a major contribution to the understanding of the pathogenesis of IBD, and
especially of the immune pathway leading to CD, can be achieved by analysis of the B cell
clones participating in immune responses in the gut, in particular their immunoglobulin (Ig)
variable region gene diversity, which has never before been studied in the context of IBD.
The adaptive immune system is one of the only two biological systems capable of continuously
learning and memorizing its experiences. This is a highly complex, distributed system, in
which pathogen recognition, decision-making and action are performed by an interacting
network of diverse lymphocytes. Immune learning and memory are embedded in the dynamical
states of the complete lymphocyte repertoire, and cannot be understood by studying the
behavior of single cell types. This complexity, further increased by the non-linear behavior
of each component, can only be elucidated by using theoretical tools to complement
experimental and clinical studies. Needless to say, many aspects of the deregulation of
lymphocyte clones are not evident in the phenotype of the single cell but rather in the
population dynamics of a whole clone (or many clones) of cells, as in B cell lymphomas. Such
aspects are best elucidated by studies of the population dynamics and genetics of the
relevant B cell clone(s).
In this study, we propose to utilize a novel bioinformatical approach – the analysis of the
shapes of Ig gene mutational lineage trees. This is the main innovative feature in our
proposal, as it taps into parameters that have never before been measured or analyzed with
respect to B lymphocytes in IBD. While the method is new, it has already been shown that
graphical analysis of B cell lineage trees and mathematical quantification of tree
properties provide novel insights into the mechanisms of normal and malignant B cell clonal
evolution. A preliminary analysis of lineage trees from other autoimmune diseases (shown
below) indicates that, given sufficient amounts of data, the method could elucidate changes
in Ig gene diversification and selection in IBD patients.
Moreover, we aim to search for correlations between the parameters characterizing Ig gene
diversification and parameters characterizing patients, disease history and severity, and
histological markers, as this has the potential of yielding novel diagnostic and prognostic
tools.
Status | Active, not recruiting |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Inflammatory Bowel Disease - Underwent colonic biopsies Exclusion Criteria: - Other diseases |
Observational Model: Defined Population, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
Israel | Department of Pathology | Tel Hashomer | |
Israel | Iris Barshack, Department of Pathology | Tel Hashomer |
Lead Sponsor | Collaborator |
---|---|
Sheba Medical Center |
Israel,
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03278912 -
Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations
|
||
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05579392 -
A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis
|
N/A | |
Completed |
NCT03264690 -
Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD Patients
|
||
Recruiting |
NCT02861053 -
Inflammatory Bowel Disease : Could a Regular Physical Activity Reduce Patients Fatigue ?
|
N/A | |
Recruiting |
NCT02275676 -
Resting Energy Expenditure and Nutritional Status in IBD
|
N/A | |
Completed |
NCT02503696 -
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
|
N/A | |
Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
Completed |
NCT02161640 -
Vascular Dysfunction in Paediatric IBD
|
N/A | |
Completed |
NCT01852760 -
Assessment of Disease Activity in Ulcerative Colitis by Endoscopic Ultrasound
|
N/A | |
Completed |
NCT01860651 -
Web-based Monitoring in Children and Adolescents With Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT01933867 -
Water-aided Colonoscopy in Inflammatory Bowel Disease Patients
|
N/A | |
Completed |
NCT01666535 -
Infliximab IBD Influenza Vaccine Study
|
N/A | |
Completed |
NCT01692743 -
Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)
|
Phase 3 | |
Completed |
NCT01676324 -
FOCUS: The Future of Fecal Calprotectin Utility Study for the Diagnosis and Management of Inflammatory Bowel Disease (IBD)
|
N/A | |
Completed |
NCT01688557 -
Trial on Innovative Technologies in Colonoscopy
|
N/A | |
Completed |
NCT01557387 -
Real-time Diagnosis of Pseudopolyps During Colonoscopy
|
||
Completed |
NCT01981616 -
Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
|
Phase 1 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01221818 -
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects
|
Phase 1 |